Login to Your Account


Orphan diseases compute: IBM bid by Novartis crashes, KPI powers up

By Randy Osborne
Staff Writer

Monday, April 17, 2017

Hoping to succeed where pharma giant Novartis AG failed in a late-stage trial, KPI Therapeutics Inc. is "working on closing out an investment round" to enable a phase II experiment with lead compound dalazatide in inclusion-body myositis (IBM), CEO Charles Magness told BioWorld Insight. "We hope to get that [financing] rolling in the summer-ish time frame," he said.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription